The management of patients with especially germline TP53 (Cases 1&4) variants is complex as clinical decision-making needs to weigh the risks of normal tissue toxicity and radiosensitivity against the tumor’s response (radioresistance and radio curability) [78]. This evidence concerns the gene TP53 and neoplasm.